NovoCure Limited

NovoCure Limited is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. NovoCure Limited is not very popular among insiders. NovoCure Limited is a mediocre stock to choose.
Log in to see more information.
Novocure Ltd. is global oncology company, which engages in the development and commercialization of...

News

TD Asset Management Inc Boosts Stock Position in NovoCure Limited (NASDAQ:NVCR)
TD Asset Management Inc Boosts Stock Position in NovoCure Limited (NASDAQ:NVCR)

Ticker Report TD Asset Management Inc boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 4.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 294,752...\n more…

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Ther
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Ther

Business Wire Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM...\n more…

Contrasting Regenicin (OTCMKTS:RGIN) & NovoCure (NASDAQ:NVCR)
Contrasting Regenicin (OTCMKTS:RGIN) & NovoCure (NASDAQ:NVCR)

Zolmax NovoCure (NASDAQ:NVCR - Get Free Report) and Regenicin (OTCMKTS:RGIN - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses...\n more…

Why NovoCure Stock Dived by 13% This Week
Why NovoCure Stock Dived by 13% This Week

Fool.com Headlines A series of C-suite changes negatively affected the share price of cancer-focused biotech NovoCure (NASDAQ: NVCR) across the holiday-shortened trading week. When the smoke cleared, the company's...\n more…

NovoCure Limited (NASDAQ:NVCR) Receives $25.50 Average Target Price from Analysts
NovoCure Limited (NASDAQ:NVCR) Receives $25.50 Average Target Price from Analysts

Zolmax NovoCure Limited (NASDAQ:NVCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat reports. Three...\n more…

Novocure announces planned CEO transition, COO to step down
Novocure announces planned CEO transition, COO to step down

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…